Key clinical point: Nemolizumab was safe and more effective than placebo in reducing the severity of atopic dermatitis (AD) or pruritus.
Major finding: Nemolizumab vs placebo significantly reduced the pruritus visual analogue scale score (weighted mean difference [WMD] −18.86; P < .001) and Eczema Area and Severity Index score ( WMD −11.76; P = .009). Adverse events were mostly mild and similar in both the groups ( P = .593).
Study details: This was a meta-analysis of 14 cohorts of participants from six randomized controlled studies that included 569 and 240 patients with AD or pruritus who received nemolizumab and placebo, respectively.
Disclosures: This study did not receive any funding. The authors declared no conflict of interests.
Source: Liang J et al. Safety and efficacy of nemolizumab for atopic dermatitis with pruritus: a systematic review and meta-regression analysis of randomized controlled trials. Front Immunol. 2022;13:825312 (Apr 26). Doi: 10.3389/fimmu.2022.825312